MESOMARK® in vitro diagnostic test for mesothelioma

Expert Opinion on Medical Diagnostics

Volumn 1, Issue 1, 2007, Pages 137-142

  Li, Zhong Qian ^a   Verch, Thorsten ^a   Allard, W Jeffrey ^a  

^a FUJIREBIO INC   (Japan)

Author keywords

ELISA; humanitarian use device; MESOMARK ; mesothelin; mesothelioma; soluble mesothelin related peptide

Indexed keywords

EID: 80052107861     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.1.1.137     Document Type: Article

References (43)

1. HOOGSTEDEN HC, LANGERAK AW, VAN DER KWAST TH, VERSNEL MA, VAN GELDER T: Malignant pleural mesothelioma. Crit. Rev. Oncol. Hematol. (1997) 25: 97-126. (Pubitemid 27168183)
2. WEILL H, HUGHES J, CHURG A: Changing trends in US mesothelioma incidence. Occup. Environ. Med. (2004) 61: 438-441. (Pubitemid 38621725)
3. HUNCHAREK M: Non-asbestos related diffuse malignant mesothelioma. Tumori (2002) 88: 1-9. (Pubitemid 34269790)
4. VAN RUTH S, BAAS P, HAAS RL, RUTGERS EJ, VERWAAL VJ, ZOETMULDER FA: Cytoreductive surgery combined with intraoperative hyperthermic intrathoracic chemotherapy for stage I malignant pleural mesothelioma. Ann. Surg. Oncol. (2000) 10: 176-182.
5. VERSCHRAEGEN C: Mesothelioma: incidence and survival rates in the United States. Proc. Am. Soc. Oncol. (2003 ):(Abstract 3495).
6. ROBINSON BWS, LAKE RA: Advances in malignant mesothelioma. N. Engl. J. Med. (2005) 353: 1591-1603. (Pubitemid 41434638)
7. CARBONE M, KRATZKE RA, TESTA JR: The pathogenesis of mesothelioma. Semin. Oncol. (2002) 29: 2-17. (Pubitemid 34163530)
8. LADOU J: The asbestos cancer epidemic. Environ. Health Perspect. (2004) 112: 285-290.
9. AULT JG, COLE RW, JENSEN CG, JENSEN LC, BACHERT LA, RIEDER CL: Behavior of crocidolite asbestos during mitosis in living vertebrate lung epithelial cells. Cancer Res. (1995) 55: 792-798.
10. KAMP DW, ISRABIAN VA, PREUSEN SE, ZHANG CX, WEITMAN SA: Asbestos causes DNA strand breaks in cultural pulmonary epithelial cells: role of iron-catalyzing free radicals. Am. J. Physiol. (1995) 268: 471-480.
11. ZANELLA CL, POSADA J, TRITTON TR, MOSSMAN BT: Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor. Cancer Res. (1996) 56: 5334-5338. (Pubitemid 27011358)
12. WONG L, ZHOU J, ANDERSON D, KRATZKE RA: Inactivation of p16INK4a expression in malignant mesothelioma by methylation. Lung Cancer (2002) 38: 131-136. (Pubitemid 35154376)
13. YANG CT, YOU L, YEH CC et al.: Adenovirus-mediated p14 (ARF) gene transfer in human mesothelioma cells. J. Natl. Cancer Inst. (2000) 92: 636-641. (Pubitemid 30321306)
14. BROADDUS VC, DANSEN TB, ABAYASIRIWARDANA KS et al.: Bid-mediates apoptotic synergy between TNF-related apoptosis-inducing ligand (TRAIL) and DNA damage. J. Biol. Chem. (2005) 280: 12486-12493.
15. MASOOD R, KUNDRA A, ZHU S et al.: Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int. J. Cancer (2003) 104: 603-610. (Pubitemid 36337260)
16. SCHERPEREEL A, GRIGORIU B, CONTI M et al.: Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am. J. Respir. Crit. Care Med. (2006) 173: 1155-1160. (Pubitemid 43726897)
17. LEE YC, LIGHT RW, MUSK AW: Management of malignant pleural mesothelioma: a critical review. Curr. Opin. Pulm. Med. (2000) 6: 267-274. (Pubitemid 30469223)
18. SUGARBAKER PH, WELCH LS, MOHAMED F, GLEHEN O: A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg. Oncol. Clin. N. Am. (2003) 12: 605-621. (Pubitemid 36920088)
19. BEYER HL, GESCHWINDT RD, GLOVER CL et al.: MESOMARKTM: a potential test for malignant pleural mesothelioma. Clin. Chem. (2007) 53: 666-672. (Pubitemid 46580236)
20. ROBINSON BWS: Soluble mesothelin-related protein - a sensitive new blood test for mesothelioma. Am. J. Oncol. Rev. (2004) 3: 230-233.
21. CULLEN MR: Serum osteopontin levels: is it time to screen asbestos-exposed workers for pleural mesothelioma? N. Engl. J. Med. (2005) 353: 1617-1618. (Pubitemid 41434643)
22. STERMAN DH, ALBELDA SM: Advances in the diagnosis, evaluation, and the management of malignant pleural mesothelioma. Respirology (2005) 10: 266-283. (Pubitemid 41025602)
23. SHITRIT D, ZINGERMAN B, SHITRIT AB, SHLOMI D, KRAMER MR: Diagnosis value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA125 assays in pleural effusions: analysis of 116 cases and review of the literature. Oncologist (2005) 10: 501-507. (Pubitemid 41266331)
24. MIEDOUGE M, ROUZAUD P, SALAMA G et al.: Evaluation of seven tumor markers in pleural fluid for the diagnosis of malignant effusions. Br. J. Cancer (1999) 81: 1059-1065. (Pubitemid 29516152)
25. ALATA F, ALATA O, METINTA M, COLAK O, HARMANCI E, DEMIR S: Diagnostic value of CEA, CA15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions. Lung Cancer (2001) 31: 9-16. (Pubitemid 32012598)
26. PASS HI, LOTT D, LONARDO F et al.: Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N. Engl. J. Med. (2005) 353: 1564-1573. (Pubitemid 41434635)
27. HASSAN R, BERA T, PASTAN I: Mesothelin: a new target for immunotherapy. Clin. Cancer Res. (2004) 10: 3937-3942. (Pubitemid 38812466)
28. ROBINSON BW, CREANEY J: Mesothelin-family proteins and diagnosis of mesothelioma. Lancet (2003) 362: 1612-1616. (Pubitemid 37443528)
29. SCHOLLER N, FU N, YANG Y et al.: Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc. Natl. Acad. Sci. USA (1999) 96: 11531-11536. (Pubitemid 29487415)
30. HO M, ONDA M, WANG QC, HASSAN R, PASTAN I, LIVELY MO: Mesothelin is shed from tumor cells. Cancer Epidemiol. Biomarkers Prev. (2006) 15: 1751.
31. MCINTOSH MW, DRESCHER C, KARLAN B et al.: Combining CA 125 and SMR serum markers for diagnosis and early detection of ovary carcinoma. Gynecol. Oncol. (2004) 95: 9-15. (Pubitemid 39286271)
32. HELLSTROM I, RAYCRAFT J, KANAN S et al.: Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol. Biomarkers Prev. (2006) 15: 1014-1020. (Pubitemid 43823532)
33. ROBINSON BW, CREANEY J: Soluble mesothelin-related protein - a blood test for mesothelioma. Lung Cancer (2005) 49 (Suppl.): S109-S111. (Pubitemid 40798859)
34. DI SERIO F, FONTANA A, LOIZZI M et al.: Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results. Clin. Chem. Lab. Med. (2007) 45: 634-638. (Pubitemid 46709735)
35. JACOBS IJ, SKATES S, DAVIES AP et al.: Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. BMJ (1996) 313: 1355-1358. (Pubitemid 26400120)
36. http://www.fdi.com/newsroom/releases/041405.pdf. Fujirebio Diagnostics Expands Commercial Availability of First Blood Test for Mesothelioma (2007).
37. http://www.mesotheliomatreatmenthelpcenter.com/Epithelioid-Mesothelioma. php. Epithelioid mesothelioma is the most common type of mesothelioma cancer cell (2007).
38. http://www.fda. gov/cdrh/pdf6/h060004c. pdf. MESOMARK: Patient information (2007).
39. http://www.fda.gov/cdrh/pdf6/h060004c.pdf. MESOMARK: Patient information (2007).
40. http://www.fda.gov/cdrh/pdf6/h060004b. pdf. Summary of safety and probable benefi t (2007).
41. http://www.fdi.com/mesomark/
42. http://irb.jhmi.edu/Guidelines/HUDGuidance#HUD. Humanitarian Use Devices (HUD) (2007).
43. http://www.fdi.com/mesomark/usa/professionals/physician-certification.php Physician certification (2007)